{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:34:51Z","timestamp":1793896491072,"version":"4.8.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.bneo.2024.100016","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T13:07:37Z","timestamp":1715260057000},"page":"100016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9951-9958","authenticated-orcid":false,"given":"Ellen","family":"Madarang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2298-7829","authenticated-orcid":false,"given":"Jillian","family":"Lykon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7336-0459","authenticated-orcid":false,"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-6524","authenticated-orcid":false,"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7464-4509","authenticated-orcid":false,"given":"Namrata S.","family":"Chandhok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-6325","authenticated-orcid":false,"given":"Justin","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8641-6415","authenticated-orcid":false,"given":"Sangeetha","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0974-8405","authenticated-orcid":false,"given":"Tulay","family":"Koru-Sengul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2507-9347","authenticated-orcid":false,"given":"Sunil Girish","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6305-2890","authenticated-orcid":false,"given":"Jason S.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1603-8930","authenticated-orcid":false,"given":"Irene","family":"Zacheo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1884-9338","authenticated-orcid":false,"given":"Agnese","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1509-6319","authenticated-orcid":false,"given":"Najla","family":"Al Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Kishtagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6309-0515","authenticated-orcid":false,"given":"Giovanni","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-8233","authenticated-orcid":false,"given":"David A.","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6519-4860","authenticated-orcid":false,"given":"Daniel A.","family":"Pollyea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3763-5504","authenticated-orcid":false,"given":"Michael R.","family":"Savona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8705-8333","authenticated-orcid":false,"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5213-5482","authenticated-orcid":false,"given":"Justin","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.bneo.2024.100016_bib1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.bneo.2024.100016_bib2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/10428194.2021.1992614","article-title":"Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches","volume":"63","author":"Przespolewski","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"10.1016\/j.bneo.2024.100016_bib3","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100016_bib4","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","article-title":"Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy","volume":"5","author":"Carter","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.bneo.2024.100016_bib5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/10428194.2017.1330956","article-title":"Acute myeloid leukemia in the elderly: therapeutic options and choice","volume":"59","author":"Webster","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"10.1016\/j.bneo.2024.100016_bib6","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920","article-title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"4","author":"Sekeres","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.bneo.2024.100016_bib7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/EDBK_239097","article-title":"More versus less therapy for older adults with acute myeloid leukemia: new perspectives on an old debate","volume":"39","author":"Klepin","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"10.1016\/j.bneo.2024.100016_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.bneo.2024.100016_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100016_bib10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2022-158518","article-title":"Long-term follow-up of the phase 3 viale-a clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy","volume":"140","author":"Pratz","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2024.100016_bib11","doi-asserted-by":"crossref","first-page":"E416","DOI":"10.1002\/ajh.26692","article-title":"Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A","volume":"97","author":"Pratz","year":"2022","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.bneo.2024.100016_bib12","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.bneo.2024.100016_bib13","doi-asserted-by":"crossref","first-page":"17914","DOI":"10.1002\/cam4.6430","article-title":"Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: pre- versus post-VIALE-A real-world experience from a predominantly US community setting","volume":"12","author":"Vachhani","year":"2023","journal-title":"Cancer Med"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100016_bib14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2022-165464","article-title":"Reduced venetoclax exposition to seven days of azacitidine is efficient in treatment-na\u00efve patients with acute myeloid leukemia","volume":"140","author":"Willekens","year":"2022","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.bneo.2024.100016_bib15","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.3390\/cancers15184618","article-title":"Venetoclax with hypomethylating agents in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of survival data from real-world studies","volume":"15","author":"Ucciero","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.bneo.2024.100016_bib16","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist"},{"issue":"24","key":"10.1016\/j.bneo.2024.100016_bib17","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.bneo.2024.100016_bib18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia [published correction appears in Blood. 2023;142(5):494]","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2024.100016_bib19","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"issue":"13","key":"10.1016\/j.bneo.2024.100016_bib20","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/bloodadvances.2022007083","article-title":"Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia","volume":"6","author":"Chua","year":"2022","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.bneo.2024.100016_bib21","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and IDH1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.bneo.2024.100016_bib22","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ajh.25484","article-title":"Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia","volume":"94","author":"Medeiros","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100016_bib23","doi-asserted-by":"crossref","first-page":"2293512","DOI":"10.1080\/16078454.2023.2293512","article-title":"Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia","volume":"29","author":"Cui","year":"2024","journal-title":"Hematology"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2024.100016_bib24","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"suppl 16","key":"10.1016\/j.bneo.2024.100016_bib25","doi-asserted-by":"crossref","first-page":"e19005","DOI":"10.1200\/JCO.2022.40.16_suppl.e19005","article-title":"Low-dose weekly decitabine and venetoclax in TP53-mutated myeloid malignancies","volume":"40","author":"Shapiro","year":"2022","journal-title":"J Clin Oncology"},{"key":"10.1016\/j.bneo.2024.100016_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106735","article-title":"RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed\/refractory acute myeloid leukemia","volume":"111","author":"Chow","year":"2021","journal-title":"Leuk Res"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T23:47:57Z","timestamp":1719359277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2950328024000165"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100016","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100016"}}